News

In 2018, in a letter approving the initiation of phase 1 clinical trials, the USFDA requested NatureWise schedule an end of phase 1 (EOP1) meeting with the FDA when NatureWise completed the phase 1 clinical program. In September 2021, NatureWise completed a phase 1 clinical trial in the USA, submitted the trial results to the USFDA along with a draft of the phase 2 study protocol for glioblastoma multiforme, and requested an EOP1 meeting. In December 2021, in the response letter for the EOP1 meeting, the USFDA commented on the trial results and suggested changes for the phase 2 clinical study [...]

NatureWise’s new chemical entity, NBM-MBX, received US Food and Drug Administration (FDA) approval on July 24th to proceed Phase I clinical trial. NBM-MBX is an isoform-selective histone deacetylase 8 (HDAC 8) inhibitor. The high specificity produces less side effects than those of non-selective HDAC inhibitors. […]

The Biotechnology Innovation Organization (BIO) is holding its 2018 International Convention from June 4 to 7 in Boston, MA, USA. […]

“NBM-BMX, a specific histone deacetylase 8 inhibitor, developed solely by NBM from scratch, has met the requirements by the "Biotech New Drug Industry Development Regulations" and other related provisions, to be recognized as an innovative new drug by Industrial Development Bureau, Ministry of Economic Affairs. With the endorsement, the company can get a number of tax-favored benefits.